Pathios founder attracts investors to $8.8M series A

With backing from investors looking to continue their support of Pathios co-founder and Executive Chairman Tom McCarthy, the company has raised $8.8 million in a series A financing round to advance its preclinical program targeting a GPCR associated with pathogenic immune signaling.

Canaan and Australia’s Medical Research Commercialisation Fund, managed by Brandon Capital,

Read the full 521 word article

How to gain access

Continue reading with a
two-week free trial.